JOHNNIE DELL: Open Payments
NPI 1528430907 · LONDON, KY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$715 in 35 payments from 11 companies in 2025. Trend: 2023 $644 · 2024 $734 · 2025 $715
Food & beverage: $715
| Company | Payments | Amount |
|---|---|---|
| Janssen Pharmaceuticals, Inc | 3 | $174 |
| ABBVIE INC. | 11 | $149 |
| AstraZeneca Pharmaceuticals LP | 2 | $137 |
| Phathom Pharmaceuticals, Inc. | 8 | $51 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $49 |
| Ardelyx, Inc. | 2 | $41 |
| Novo Nordisk Inc | 2 | $35 |
| Verona Pharma, Inc. | 1 | $22 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $20 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $19 |
Products named: SPRAVATO, VRAYLAR, FARXIGA, VOQUEZNA, CAPLYTA, IBSRELA, Ozempic, Ohtuvayre.
Industry payments across KY — which companies pay providers there.
